Table 1 DNA prevalence of HPyV6 and HPyV7 in different patient groups
From: HPyV6 and HPyV7 in urine from immunocompromised patients
Patient group (n) | HPyV6 (%) | HPyV7 (%) |
|---|---|---|
SLE (5) | ||
SLE1 (5 samples) | 1 (20.0) | 0 (0) |
SLE2 (7 samples) | 1 (14.3) | 0 (0) |
SLE3 (13 samples) | 4 (30.8) | 2 (15.4)a |
SLE4 (16 samples) | 4 (25.0) | 3 (18.8)b |
SLE5 (32 samples) | 11 (34.4) | 1 (3.1)c |
Total samples (73) | 21 (28.8) | 6 (8.2) |
Multiple sclerosis (30) | 0 (0) | 0 (0) |
Psoriasis vulgaris (15) | 0 (0) | 0 (0) |
Arthritic psoriasis (15) | 0 (0) | 0 (0) |
HIV-positive (66) | 6 (9.1) | 0 (0) |
Pregnant women (47) | 19 (40.4) | 4 (8.5)d |
Blood donors (20) | 0 (0) | 0 (0) |